Oxidative Stress Induces a VEGF Autocrine Loop in the Retina: Relevance for Diabetic Retinopathy
暂无分享,去创建一个
[1] G. A. Limb,et al. In vitro response and gene expression of human Retinal Müller cells treated with different Anti-VEGF drugs. , 2020, Experimental eye research.
[2] Giovanni Casini,et al. Relationships Between Neurodegeneration and Vascular Damage in Diabetic Retinopathy , 2019, Front. Neurosci..
[3] S. Langdon,et al. Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies , 2019, Cancer drug resistance.
[4] Q. Ren,et al. Baicalin relieves hypoxia-aroused H9c2 cell apoptosis by activating Nrf2/HO-1-mediated HIF1α/BNIP3 pathway , 2019, Artificial cells, nanomedicine, and biotechnology.
[5] S. D. De Smedt,et al. Müller cells as a target for retinal therapy. , 2019, Drug discovery today.
[6] Giovanni Casini,et al. Nutraceuticals for the Treatment of Diabetic Retinopathy , 2019, Nutrients.
[7] M. Cammalleri,et al. Lisosan G Protects the Retina from Neurovascular Damage in Experimental Diabetic Retinopathy , 2018, Nutrients.
[8] K. Martin,et al. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies , 2018, Expert opinion on biological therapy.
[9] Jin Yao,et al. Gαi1 and Gαi3mediate VEGF-induced VEGFR2 endocytosis, signaling and angiogenesis , 2018, Theranostics.
[10] Matthew Slattery,et al. Identification of a functional antioxidant response element at the HIF1A locus , 2018, Redox biology.
[11] Yoon Kyung Choi,et al. Heme oxygenase metabolites improve astrocytic mitochondrial function via a Ca2+-dependent HIF-1α/ERRα circuit , 2018, PloS one.
[12] M. Lulli,et al. Nanoparticle-Mediated Delivery of Neuroprotective Substances for the Treatment of Diabetic Retinopathy , 2018, Current neuropharmacology.
[13] Wei Wang,et al. Diabetic Retinopathy: Pathophysiology and Treatments , 2018, International journal of molecular sciences.
[14] P. Fort,et al. Role of Inflammation in Diabetic Retinopathy , 2018, International journal of molecular sciences.
[15] D. Tuveson,et al. Transcriptional Regulation by Nrf2 , 2017, Antioxidants & redox signaling.
[16] Y. Wada,et al. The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis , 2017, Oncotarget.
[17] A. Sholl-Franco,et al. Cellular stress response in human Müller cells (MIO‐M1) after bevacizumab treatment , 2017, Experimental eye research.
[18] Y. Le. VEGF production and signaling in Müller glia are critical to modulating vascular function and neuronal integrity in diabetic retinopathy and hypoxic retinal vascular diseases , 2017, Vision Research.
[19] A. Ferrigno,et al. Autocrine and Paracrine Secretion of Vascular Endothelial Growth Factor in the Pre-Hypoxic Diabetic Retina. , 2017, Current diabetes reviews.
[20] M. Mishra,et al. Epigenetic regulation of redox signaling in diabetic retinopathy: Role of Nrf2 , 2017, Free radical biology & medicine.
[21] Han-dong Wang,et al. Interplay between VEGF and Nrf2 regulates angiogenesis due to intracranial venous hypertension , 2016, Scientific Reports.
[22] J. Mercer,et al. VEGF induces signalling and angiogenesis by directing VEGFR2 internalisation through macropinocytosis , 2016, Journal of Cell Science.
[23] M. Ferrer,et al. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. , 2016, ACS chemical biology.
[24] Mieke Dewerchin,et al. Vascular endothelial growth factor: a neurovascular target in neurological diseases , 2016, Nature Reviews Neurology.
[25] M. Cammalleri,et al. VEGF as a Survival Factor in Ex Vivo Models of Early Diabetic Retinopathy. , 2016, Investigative ophthalmology & visual science.
[26] R. Simó,et al. Neuroprotection as a Therapeutic Target for Diabetic Retinopathy , 2016, Journal of diabetes research.
[27] A. Bullock,et al. Structural basis of Keap1 interactions with Nrf2 , 2015, Free radical biology & medicine.
[28] T. Behl,et al. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. , 2015, Pharmacological research.
[29] Y. Le,et al. Müller Glia Are a Major Cellular Source of Survival Signals for Retinal Neurons in Diabetes , 2015, Diabetes.
[30] C. Costagliola,et al. Diabetic Retinopathy: Vascular and Inflammatory Disease , 2015, Journal of diabetes research.
[31] E. Borsi,et al. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. , 2015, Translational research : the journal of laboratory and clinical medicine.
[32] Sergio Capaccioli,et al. A pathophysiological view of the long non-coding RNA world , 2014, Oncotarget.
[33] Xianming Deng,et al. Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis , 2014, Cancer biology & therapy.
[34] Xin Xie,et al. Blocking autocrine VEGF signaling by sunitinib, an anti-cancer drug, promotes embryonic stem cell self-renewal and somatic cell reprogramming , 2014, Cell Research.
[35] Tetsuro Ohba,et al. Autocrine VEGF/VEGFR1 Signaling in a Subpopulation of Cells Associates with Aggressive Osteosarcoma , 2014, Molecular Cancer Research.
[36] Xian-min Xiao,et al. Upregulated autocrine vascular endothelial growth factor (VEGF)/VEGF receptor‐2 loop prevents apoptosis in haemangioma‐derived endothelial cells , 2014, The British journal of dermatology.
[37] F. Agani,et al. Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. , 2013, Current Cancer Drug Targets.
[38] J. Roider,et al. Regulation of constitutive vascular endothelial growth factor secretion in retinal pigment epithelium/choroid organ cultures: p38, nuclear factor kappaB, and the vascular endothelial growth factor receptor-2/phosphatidylinositol 3 kinase pathway , 2013, Molecular vision.
[39] E. Catalani,et al. Vascular endothelial growth factor in the ischemic retina and its regulation by somatostatin , 2012, Journal of neurochemistry.
[40] P. Bagnoli,et al. Mechanisms underlying somatostatin receptor 2 down‐regulation of vascular endothelial growth factor expression in response to hypoxia in mouse retinal explants , 2012, The Journal of pathology.
[41] T. Pufe,et al. Interplay between Vascular Endothelial Growth Factor (VEGF) and Nuclear Factor Erythroid 2-related Factor-2 (Nrf2) , 2011, The Journal of Biological Chemistry.
[42] A. Zannettino,et al. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma , 2011, Leukemia.
[43] A. Balbarini,et al. Hypoxia effects on proangiogenic factors in human umbilical vein endothelial cells: functional role of the peptide somatostatin , 2011, Naunyn-Schmiedeberg's Archives of Pharmacology.
[44] Sheng-Kwei Song,et al. Vitreous Volume of the Mouse Measured by Quantitative High-Resolution MRI , 2010 .
[45] H. Lee,et al. Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt. , 2010, Investigative ophthalmology & visual science.
[46] Magali Saint-Geniez,et al. Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors , 2008, PloS one.
[47] M. Bartoli,et al. Vascular endothelial growth factor in eye disease , 2008, Progress in Retinal and Eye Research.
[48] Kazuhiro Takahashi,et al. Fasudil-induced hypoxia-inducible factor-1α degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells , 2008, Molecular Cancer Therapeutics.
[49] C. Caramelo,et al. Induction of Hypoxia-inducible Factor 1α Gene Expression by Vascular Endothelial Growth Factor* , 2008, Journal of Biological Chemistry.
[50] Kenneth P. Roos,et al. Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.
[51] Mikko Nikinmaa,et al. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. , 2006, Experimental eye research.
[52] C. Caramelo,et al. Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. , 2006, American journal of physiology. Heart and circulatory physiology.
[53] F. Orsenigo,et al. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments , 2006, The Journal of cell biology.
[54] M. Bartoli,et al. VEGF differentially activates STAT3 in microvascular endothelial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[55] Jong-Wan Park,et al. Oxygen-dependent and -independent regulation of HIF-1alpha. , 2002, Journal of Korean medical science.
[56] B. Terman,et al. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization , 1999, Oncogene.
[57] Y. Le,et al. VEGF as a Trophic Factor for Müller Glia in Hypoxic Retinal Diseases. , 2018, Advances in experimental medicine and biology.
[58] M. Friedlander,et al. Hypoxia-inducible factor (HIF)/vascular endothelial growth factor (VEGF) signaling in the retina. , 2014, Advances in experimental medicine and biology.
[59] J. Roider,et al. Mechanisms of Pathological VEGF Production in the Retina and Modification with VEGF-Antagonists , 2012 .